NO308600B1 - Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene - Google Patents

Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene

Info

Publication number
NO308600B1
NO308600B1 NO964093A NO964093A NO308600B1 NO 308600 B1 NO308600 B1 NO 308600B1 NO 964093 A NO964093 A NO 964093A NO 964093 A NO964093 A NO 964093A NO 308600 B1 NO308600 B1 NO 308600B1
Authority
NO
Norway
Prior art keywords
alkyl
opt
alkoxy
substd
cycloalkyl
Prior art date
Application number
NO964093A
Other languages
English (en)
Norwegian (no)
Other versions
NO964093L (no
NO964093D0 (no
Inventor
Klaus Weidmann
Karl-Heinz Baringhaus
Georg Tschank
Martin Bickel
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19536263A external-priority patent/DE19536263A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO964093D0 publication Critical patent/NO964093D0/no
Publication of NO964093L publication Critical patent/NO964093L/no
Publication of NO308600B1 publication Critical patent/NO308600B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO964093A 1995-09-28 1996-09-27 Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene NO308600B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19536263A DE19536263A1 (de) 1995-09-28 1995-09-28 Substituierte Chinolin-2-carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19605170 1996-02-13

Publications (3)

Publication Number Publication Date
NO964093D0 NO964093D0 (no) 1996-09-27
NO964093L NO964093L (no) 1997-04-01
NO308600B1 true NO308600B1 (no) 2000-10-02

Family

ID=26019051

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964093A NO308600B1 (no) 1995-09-28 1996-09-27 Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene

Country Status (20)

Country Link
US (2) US5719164A (fr)
EP (1) EP0765871B1 (fr)
JP (1) JPH09124606A (fr)
KR (1) KR970061869A (fr)
CN (2) CN1120157C (fr)
AT (1) ATE263155T1 (fr)
AU (1) AU728208B2 (fr)
CA (1) CA2186717A1 (fr)
CZ (1) CZ283396A3 (fr)
DE (1) DE59610950D1 (fr)
ES (1) ES2215184T3 (fr)
HU (1) HUP9602685A3 (fr)
IL (2) IL135495A (fr)
MX (1) MX9604378A (fr)
MY (1) MY133647A (fr)
NO (1) NO308600B1 (fr)
NZ (1) NZ299455A (fr)
PL (1) PL316321A1 (fr)
SG (1) SG45503A1 (fr)
SI (1) SI9600287A (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19650215A1 (de) * 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US20020198145A1 (en) * 1999-06-10 2002-12-26 Cognetix, Inc. MuO-conopeptides and their use as local anesthetics
CA2432642A1 (fr) * 2000-12-21 2002-08-08 Subhash P. Khanapure Composes aryle substitues en tant que nouveaux inhibiteurs selectifs de la cyclo-oxygenase-2, compositions et methodes d'utilisation
WO2002074981A2 (fr) * 2001-03-21 2002-09-26 Isis Innovation Ltd. Dosages, procedes et dispositifs
US20030176317A1 (en) 2001-12-06 2003-09-18 Volkmar Guenzler-Pukall Stabilization of hypoxia inducible factor (HIF) alpha
EP2295060B1 (fr) 2001-12-06 2018-10-31 Fibrogen, Inc. Traitement de conditions ischémiques ou hypoxiques
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
PL1644336T3 (pl) 2003-06-06 2011-07-29 Fibrogen Inc Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005034929A2 (fr) * 2003-10-10 2005-04-21 Fibrogen, Inc. Remodelage et vascularisation de tissus
JP5390184B2 (ja) * 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
CN101242817B (zh) 2005-06-15 2016-08-31 菲布罗根公司 HIF1α调节剂在治疗癌症中的用途
MX2008001033A (es) 2005-07-27 2008-03-19 Hoffmann La Roche Derivados de 4-ariloxi quinolina como moduladores de 5-ht6.
US7728130B2 (en) 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
MX2008009581A (es) 2006-01-27 2009-01-07 Fibrogen Inc Compuestos de cianoisoquinolina que estabilizan el factor inducible hipoxia (fih).
WO2007101204A1 (fr) * 2006-02-27 2007-09-07 Alcon Research, Ltd. Méthode de traitement du glaucome
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
WO2007114612A1 (fr) * 2006-03-30 2007-10-11 Lg Electronics Inc. Procédé et dispositif de codage/décodage d'un signal vidéo
MX2008012734A (es) * 2006-04-04 2009-01-29 Fibrogen Inc Compuestos pirrolo- y tiazolo-piridina como moduladores del factor inducible de hipoxia (hif).
EP3026044B8 (fr) 2006-06-26 2018-12-19 Akebia Therapeutics, Inc. Inhibiteurs de prolyl hydroxylase et procédés d'utilisation
WO2008076427A2 (fr) * 2006-12-18 2008-06-26 Amgen Inc. Composés de naphtalénone présentant une activité inhibititrice de prolyle hydroxylase, compositions et utilisations de ceux-ci
EP2097416B1 (fr) * 2006-12-18 2012-09-12 Amgen, Inc Composés d'azaquinolone possédant une activité inhibitrice de prolyl hydroxylase, compositions et utilisations correspondantes
JP2010524942A (ja) * 2007-04-18 2010-07-22 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼを阻害するキノロン及びアザキノロン
US7569726B2 (en) * 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
EP2150251B9 (fr) * 2007-05-04 2013-02-27 Amgen, Inc Derives de la thienopyridine et de la thiazolopyridine qui inhibent l'activite prolyle hydroxylase
AU2008248165B2 (en) * 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
US8927591B2 (en) 2008-11-14 2015-01-06 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
GEP201606506B (en) * 2009-12-17 2016-07-11 Merck Sharp & Dohme Quinoline amide m1 receptor positive allosteric modulators
UA113507C2 (xx) 2011-02-07 2017-02-10 Модулятори s1p
NO2686520T3 (fr) 2011-06-06 2018-03-17
US9409892B2 (en) 2012-03-09 2016-08-09 Fibrogen, Inc. 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors
ES2631655T3 (es) 2012-07-16 2017-09-01 Fibrogen, Inc. Procedimiento para fabricar compuestos de isoquinolina
SI3470397T1 (sl) 2012-07-16 2022-07-29 Fibrogen, Inc. Kristalinične oblike zaviralca prolil hidroksilaze
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP2877166B1 (fr) * 2012-07-27 2018-02-28 Biogen MA Inc. Dérivés de 1-[7-(cis-4-méthyl-cyclohexyloxy)-8-trifluoromethyl-naphthalen-2-ylméthyl]-pipéridine-4-acide carboxylique en tant que modulateurs d'autotaxin (ATX) pour le traitement d'inflammations et des maladies auto-immunes
KR102233081B1 (ko) 2013-01-24 2021-03-29 피브로겐, 인크. 〔[1-시아노-5-(4-클로로페녹시)-4-하이드록시-아이소퀴놀린-3-카보닐]-아미노〕-아세트산의 결정 형태
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
WO2016118858A1 (fr) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Formes solides d'acide 2-(5-(3-fluorophényl)-3-hydroxypicolinamido)acétique, compositions et utilisation dudit acide
BR112017021097B1 (pt) 2015-04-01 2024-01-02 Akebia Therapeutics, Inc Formulação de dosagem oral e seu uso
TWI822776B (zh) 2018-05-09 2023-11-21 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
CN113302175A (zh) 2018-11-09 2021-08-24 维瓦斯治疗公司 双环化合物
WO2020214734A1 (fr) 2019-04-16 2020-10-22 Vivace Therapeutics, Inc. Composés bicycliques
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
EP0541042A1 (fr) * 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft Dérivés d'acide pyridine 2,4- et 2,5-dicarboxyliques, leur procédé de préparation et leur utilisation comme médicaments
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4233124A1 (de) * 1992-10-02 1994-04-07 Hoechst Ag Acylsulfonamido- und Sulfonamidopyridin-2-carbonsäureester sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK122693D0 (da) * 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
ES2101420T3 (es) * 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
EP0650961B1 (fr) * 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Amides d'acide carboxylique hétérocycliques substitués, leur preparation et leur utilisation comme médicaments
NZ270267A (en) * 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
ES2215184T3 (es) 2004-10-01
NO964093L (no) 1997-04-01
JPH09124606A (ja) 1997-05-13
PL316321A1 (en) 1997-04-01
IL135495A (en) 2002-12-01
US5719164A (en) 1998-02-17
MY133647A (en) 2007-11-30
HU9602685D0 (en) 1996-11-28
NO964093D0 (no) 1996-09-27
ATE263155T1 (de) 2004-04-15
CN1282737A (zh) 2001-02-07
MX9604378A (es) 1997-03-29
SG45503A1 (en) 1998-01-16
EP0765871B1 (fr) 2004-03-31
SI9600287A (en) 1997-04-30
CZ283396A3 (en) 1997-04-16
CA2186717A1 (fr) 1997-03-29
EP0765871A1 (fr) 1997-04-02
CN1154365A (zh) 1997-07-16
AU728208B2 (en) 2001-01-04
AU6583896A (en) 1997-04-10
HUP9602685A2 (hu) 1998-09-28
CN1120157C (zh) 2003-09-03
NZ299455A (en) 1997-06-24
HUP9602685A3 (en) 2001-04-28
IL119302A0 (en) 1996-12-05
US5726305A (en) 1998-03-10
DE59610950D1 (de) 2004-05-06
KR970061869A (ko) 1997-09-12

Similar Documents

Publication Publication Date Title
NO308600B1 (no) Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene
FI943579A (fi) Bentsokondensoituja 5-rengasheterosyklejä, menetelmä niiden valmistamiseksi, niiden käyttö lääkkeinä, niiden käyttö diagnostisina aineina sekä niitä sisältävät lääkkeet
DK436289D0 (da) Cycloalkyl-substituerede glutaramidderivater, farmaceutiske praeparater indeholdende disse forbindelser, forbindelserne til medicinsk anvendelse og deres anvendelse til fremstilling af laegemidler til behandling af hypertension, hjertesvigt eller renal insufficiens
IE881994L (en) Substituted azepines and pyrrolidines
PH24782A (en) Composition containing a penem or carbapenem antibiotic and the use of the same
IL105020A0 (en) Carbapenem derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
HUT34210A (en) Process for producing new cepheme-carboxylic acid derivatives and pharmaceutical compositions containing them as active ingredients
AU1998995A (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
NZ201895A (en) 2-beta-substituted-2-alpha-methyl-(5r)-penam-3-alpha-carboxylic acid 1,1-dioxides;intermediates and pharmaceutical compositions
US5378844B1 (en) 8-(1-aminocycloalkyl)-1,3-dialkylxanthine derivatives preparation process and antidepressant nootropic and psychostimulant composition thereof
EP0331871A3 (en) Imidazobenzodiazepine with antipsychotic activity
BR1100564A (pt) Formas cristalinas de mono-hidrato do cloridrato de endo-2,3-dihidro-n-(8-metil-8-azabiciclo[3.2.1]oct-3-il)-2 - -oxo-1h-benzimidazol-1-carboxamida e de mono-hidrato do cloridrato de endo-3-etil-2,3-di-hidro-n-(8-metil-8-azabiciclo[3.2.1]oc t-3-il)-2-oxo-1h-benzimidazol-1-carboxamida como antagonistas do 5-ht
IE35218L (en) Azepine derivatives
ITTE930001A0 (it) Procedimento per l'arricchimento del tenore in zeoliti di sottoprodot-ti delle cave di blocchetti di "tufo litoide"
IT1233837B (it) Derivati diidropiridinici, loro preparazione e impieghi farmaceutici.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees